Demonstration of mutations conferring resistance to lamivudine in liver tissue of chronic hepatitis B patients under lamivudine therapy

Authors

İSMAİL YAŞAR AVCI
CAN POLAT EYİGÜN
EMİNE GÜNAL
AYHAN KUBAR
HANEFİ CEM GÜL
ÖMER COŞKUN
HAKAN ERDEM
LEVENT GÖRENEK
BÜLENT AHMET BEŞİRBELLİOĞLU

DOI

10.3906/sag-1108-16

Abstract

To demonstrate the genotypic lamivudine resistance in liver tissue of patients with negative serum hepatitis B virus (HBV) DNA under long-term lamivudine therapy. Materials and methods: Fourteen patients (10 patients with elevated alanine aminotransferase and 4 patients under long-term lamivudine therapy for severe liver disease) with undetected serum HBV DNA were included in the study. A liver biopsy was performed for each patient, and HBV DNA extracted from liver tissue was analyzed with TaqMan real-time polymerase chain reaction. Results: Mutations conferring lamivudine resistance were shown for all 14 patients in their liver tissue-extracted HBV DNA. One patient had rtM204V, 4 patients had rtL180M, 2 had rtL180M + rtM204V, 4 had rtL180M + rtM204I, and 3 had rtL180M + rtM204I + rtM204V substitutions. Conclusion: Analyzing mutation in liver tissues of these patients might help demonstrate resistance earlier and prevent delaying of therapeutic modification. Therefore, all liver biopsy specimens of patients with severe liver fibrosis should be analyzed using the molecular technique.

Keywords

Mutation, liver tissue, HBV DNA

First Page

199

Last Page

202

Recommended Citation

AVCI, İSMAİL YAŞAR; EYİGÜN, CAN POLAT; GÜNAL, EMİNE; KUBAR, AYHAN; GÜL, HANEFİ CEM; COŞKUN, ÖMER; ERDEM, HAKAN; GÖRENEK, LEVENT; and BEŞİRBELLİOĞLU, BÜLENT AHMET (2013) "Demonstration of mutations conferring resistance to lamivudine in liver tissue of chronic hepatitis B patients under lamivudine therapy," Turkish Journal of Medical Sciences: Vol. 43: No. 2, Article 3. https://doi.org/10.3906/sag-1108-16
Available at: https://journals.tubitak.gov.tr/medical/vol43/iss2/3